Universal Detection Technology ( www.udetection.com ) (OTCBB: UNDT), a reseller of early-warning monitoring technologies that protect against biological, chemical, and radiological threats, announced today that its revenues for the quarter ended June 30, 2011 were the highest in more than two years. The increase is primarily due to high demand for radiation detection equipment both domestically and internationally. The Company is also beginning to see increased sales from its newly remodeled online store , which can be viewed at http://shop.udetection.com/en/1-home .
Statements in this news release about IsoRay's future expectations, including: the advantages of our Cesium-131 seed, the advantages of Cesium-131, the mesh brachytherapy application and the da Vinci® surgery system in lung cancer applications, whether IsoRay's Cesium-131 seed will be used to treat additional cancers and malignant disease, whether the use of Cesium-131 to treat lung cancers will be successful both long- and short-term in the initial and any future implants, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of early clinical studies, whether implants of Cesium-131 to treat lung cancers result in favorable patient outcomes, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, whether hospitals, medical treatment centers and physicians continue to adopt Cs-131 mesh brachytherapy used in conjunction with the da Vinci® surgical system to treat early stage lung cancers, successful completion of future research and development activities, and other risks detailed from time to time in IsoRay's reports filed with the SEC.Important Safety Information for HylatopicPlus™ CreamIsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy treatment represents one of the most important advancements in internal radiation therapy in 20 years. In addition to its CMS codes, Cesium-131 is FDA-cleared for the treatment of prostate, lung, ocular melanoma, brain, colorectal, gynecological, and head and neck cancer and other cancers throughout the body.Safe Harbor Statement"We are pleased with our revenue growth from the previous quarter and we are on pace for another increase in the next quarter. We have also continually expanded our product offerings throughout the CBRN spectrum and are continuing to grow and nurture our distribution networks. Our plans for the remainder of 2011 include, expanding our sales force, expanding targeted regional advertising, and having more exhibitions at targeted trade shows. Also, as we receive feedback from our customers, we will be taking R&D initiatives to develop products suited for customers in the markets we serve," said Jacques Tizabi, UNDT's Chairman and CEO.Except for historical information contained herein, the statements in this news release are forward-looking statements that involve known and unknown risks and uncertainties, which may cause the Company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.Forward Looking Statements
Universal Detection Technology Email Contact
No comments:
Post a Comment